Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282762 · ClinicalTrials.gov registry record
Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease
A clinical trial, sponsored by Dynavax Technologies Corporation.
- Completed
- Registry status
- 147
- Enrollment target
NCT01282762: Completed study, sponsored by Dynavax Technologies Corporation.
NCT01282762 is a clinical trial that has completed, run by Dynavax Technologies Corporation. The registered enrollment target is 147 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01282762 has completed, sponsored by Dynavax Technologies Corporation.
- COMPLETED
- Registry status
- 147 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the durability of seroprotection of HEPLISAV™ and Engerix-B® and the number of injections of each vaccine needed to maintain seroprotection in a cohort of chronic kidney disease (CKD) patients over time.
Interventions
- BIOLOGICAL Engerix-B
- BIOLOGICAL HEPLISAV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-08 |
What the finished NCT01282762 record still lists
NCT01282762 is an observational study that tracks outcomes without assigning an intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Engerix-B is the first listed.
NCT01282762 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01282762 about?
NCT01282762 is a clinical study titled "Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease". The purpose of this study is to determine the durability of seroprotection of HEPLISAV™ and Engerix-B® and the number of injections of each vaccine needed to maintain seroprotection in a cohort of chronic kidney disease (CKD) patients over time.
What is the current status of trial NCT01282762?
This trial is currently completed. The enrollment target is 147 participants. The study started on 2010-12. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01282762?
The interventions under investigation include: Engerix-B (BIOLOGICAL), HEPLISAV (BIOLOGICAL).
Who is sponsoring clinical trial NCT01282762?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia